Literature DB >> 10704524

Human alpha-N-acetylgalactosaminidase: site occupancy and structure of N-linked oligosaccharides.

M Ohta1, T Ohnishi, Y A Ioannou, M E Hodgson, F Matsuura, R J Desnick.   

Abstract

Human alpha-N-acetylgalactosaminidase (alpha-GalNAc; also known as alpha-galactosidase B) is the lysosomal exoglycohydrolase that cleaves alpha-N-acetylgalactosaminyl moieties in glycoconjugates. Mutagenesis studies indicated that the first five (N124, N177, N201, N359, and N385) of the six potential N-glycosylation sites were occupied. Site 3 occupancy was important for enzyme function and stability. Characterization of the N-linked oligosaccharide structures on the secreted enzyme overexpressed in Chinese hamster ovary cells revealed highly heterogeneous structures consisting of complex (approximately 53%), hybrid (approximately 12%), and high mannose-type (approximately 33%) oligosaccharides. The complex structures were mono-, bi-, 2,4-tri-, 2,6-tri-, and tetraantennary, among which the biantennary structures were most predominant (approximately 53%). Approximately 80% of the complex oligo-saccharides had a core-region fucose and 50% of the complex oligosaccharides were sialylated exclusively with alpha-2,3-linked sialic acid residues. The majority of hybrid type oligo-saccharides were GalGlcNAcMan(6)GlcNAc-Fuc(0-1)GlcNAc. Approximately 54% of the hybrid oligosaccharide were phosphorylated and one-third of these structures were further sialylated, the latter representing unique phosphorylated and sialylated structures. Of the high mannose oligosaccharides, Man(5-7)GlcNAc(2) were the predominant species (approximately 90%) and about 50% of the high mannose oligosaccharides were phosphorylated, exclusively as monoesters whose positions were determined. Comparison of the oligosaccharide structures of alpha-GalNAc and alpha-galactosidase A, an evolutionary-related and highly homologous exoglycosidase, indicated that alpha-GalNAc had more completed complex chains, presumably due to differences in enzyme structure/domains, rate of biosynthesis, and/or aggregation of the overexpressed recombinant enzymes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10704524     DOI: 10.1093/glycob/10.3.251

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  2 in total

1.  Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease.

Authors:  Youichi Tajima; Ikuo Kawashima; Takahiro Tsukimura; Kanako Sugawara; Mayuko Kuroda; Toshihiro Suzuki; Tadayasu Togawa; Yasunori Chiba; Yoshifumi Jigami; Kazuki Ohno; Tomoko Fukushige; Takuro Kanekura; Kohji Itoh; Toya Ohashi; Hitoshi Sakuraba
Journal:  Am J Hum Genet       Date:  2009-10-22       Impact factor: 11.025

2.  The 1.9 a structure of human alpha-N-acetylgalactosaminidase: The molecular basis of Schindler and Kanzaki diseases.

Authors:  Nathaniel E Clark; Scott C Garman
Journal:  J Mol Biol       Date:  2009-08-14       Impact factor: 5.469

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.